about
Platelet polyphosphates are proinflammatory and procoagulant mediators in vivoPlatelets in Pulmonary Immune Responses and Inflammatory Lung DiseasesNew Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?Do neutrophil extracellular traps contribute to the heightened risk of thrombosis in inflammatory diseases?Endothelial cell control of thrombosisDrug carrier interaction with blood: a critical aspect for high-efficient vascular-targeted drug delivery systemsAnticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decadeRivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practiceP2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cellsDabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisonsThe pharmacological landscape and therapeutic potential of serine hydrolasesThrombus-Targeted Theranostic Microbubbles: A New Technology towards Concurrent Rapid Ultrasound Diagnosis and Bleeding-free Fibrinolytic Treatment of Thrombosis.Quantifying progression and regression of thrombotic risk in experimental atherosclerosisProtective and detrimental effects of neuroectodermal cell–derived tissue factor in mouse models of strokeStructure, sulfatide binding properties, and inhibition of platelet aggregation by a disabled-2 protein-derived peptide.Platelets and platelet adhesion molecules: novel mechanisms of thrombosis and anti-thrombotic therapiesAn update on recent patents on thrombin inhibitors (2010 - 2013)Replication and characterisation of genetic variants in the fibrinogen gene cluster with plasma fibrinogen levels and haematological traits in the Third National Health and Nutrition Examination SurveyCoulomb nanoradiator-mediated, site-specific thrombolytic proton treatment with a traversing pristine Bragg peakNanomedicine as a strategy to fight thrombotic diseases.Syntaxin-binding protein STXBP5 inhibits endothelial exocytosis and promotes platelet secretion.Inhibitory effect of caffeic acid on ADP-induced thrombus formation and platelet activation involves mitogen-activated protein kinases.Sulfatides partition disabled-2 in response to platelet activation.New parenteral anticoagulants in development.Controlling coagulation dysregulation in xenotransplantation.Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp).Erythrocyte-platelet interaction in uncomplicated pregnancy.Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond.Recent Progress in Research on the Pathogenesis of Pulmonary Thromboembolism: An Old Story with New Perspectives.Secretion of von Willebrand factor by endothelial cells links sodium to hypercoagulability and thrombosis.Targeting GPVI as a novel antithrombotic strategy.Modern role for clopidogrel in management of atrial fibrillation and stroke reductionUnique extracellular matrix heparan sulfate from the bivalve Nodipecten nodosus (Linnaeus, 1758) safely inhibits arterial thrombosis after photochemically induced endothelial lesion.Vascular injury involves the overoxidation of peroxiredoxin type II and is recovered by the peroxiredoxin activity mimetic that induces reendothelialization.Synthesis and Thrombin, Factor Xa and U46619 Inhibitory Effects of Non-Amidino and Amidino N²-Thiophenecarbonyl- and N²-Tosylanthranilamides.New options with dabigatran etexilate in anticoagulant therapyIn situ crosslinkable heparin-containing poly(ethylene glycol) hydrogels for sustained anticoagulant release.Factor XIII activity mediates red blood cell retention in venous thrombi.Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparinsSelf-titrating anticoagulant nanocomplexes that restore homeostatic regulation of the coagulation cascade.
P2860
Q24655664-A14CC693-15C4-47A2-B37E-AF624E264BAFQ26739670-71438A7E-C0BF-4710-AF31-01D318BA331DQ26765488-1A2BB886-DB19-4D00-8376-0F758275D071Q26771128-A44AD88F-721D-4922-B547-51276F7772A7Q26781779-6CBE92AD-BA4F-4708-BDA8-F310DD58B89CQ26798467-86434007-3396-455B-94DB-5A3DBA3DFB66Q26824864-ACD8A298-EE90-43A7-816B-3119A00FE000Q26825230-9098B514-25E9-40A7-9137-C01C89625121Q26861200-7AFA61E3-4F23-487B-A073-8E53F7164DB5Q26995635-E20C9B3D-E5FA-4C7A-8ED3-BDF757BEA3A8Q26995817-A63A9699-3C53-4DCD-95CC-E015154D45C4Q27300813-7A77DA0B-648B-45E3-AE5C-3F96DAA9A59AQ27318779-44F9E02F-9730-44EC-A2F1-73DA86EA4D6AQ27333861-8D0AD0F5-C9DB-49C9-9765-EF6BA031E5ACQ27673101-F6C2A510-9AF1-424E-B4B7-5F7CE6418D2BQ28068448-ED9D2116-6C63-443A-BEC0-E74B06B75CC9Q28299898-96C13EED-09D4-44A5-B1D6-97D4C00189FCQ28384226-55204006-B7CF-40E0-A21C-85D1BBB49BA9Q28818398-F06D56D7-20E8-4BCC-8524-D68A7B228C97Q30367197-CA92A109-7937-47C7-B57F-ADDC268834ABQ30590837-9F4DFBC8-D53E-4C5F-9E4D-4CB8D9B0C1D3Q30663919-F22C1CBC-F237-4DC6-9CD8-0F1B98F67841Q30942858-56D56FB6-0427-4B4B-B748-AD46D7AADC2CQ33392647-300E3BD8-3D5C-4A54-B619-40C9DFA64A53Q33394542-5B4E8ADA-94E2-46F4-B7BD-F32BFFB247A1Q33397879-C1DBD475-3CD5-461E-85F5-22EC6B0F53F6Q33419140-57312272-93EE-4D22-870E-47EA84204E7FQ33432917-DC389041-B91D-4FAE-8EA6-4247BC9F2B3FQ33581791-2C6EBF84-5592-44EA-A3DB-99C2E0D7F530Q33674556-66BDDC7A-96E8-46B7-B13C-DB7429E16419Q33689745-DDB63D32-E138-4B9E-8E3F-CC153E7D544DQ33715413-CA9864D5-79FD-4D44-BAA3-D41D2924B00CQ33748076-90524C21-257C-40C5-A501-3BCA4B9FCB25Q33821624-C043039A-D5F5-4E58-8B14-7BCA23094005Q33838499-3E7DC571-DB12-4B97-8537-CAA83E4BA65CQ33888320-23CA698F-D570-4E27-816B-0561D4595492Q33894433-0B4148BF-A8D2-4B0D-B1FE-64D862770322Q33944224-FF6C1801-F57E-4B88-A9A9-FA2D8A2CBB68Q34228210-AD6EB271-5456-4259-9D60-68317AB314F0Q34239129-817983C1-2AC4-4EA5-9F12-2BA04A55FEE9
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Triggers, targets and treatments for thrombosis.
@ast
Triggers, targets and treatments for thrombosis.
@en
type
label
Triggers, targets and treatments for thrombosis.
@ast
Triggers, targets and treatments for thrombosis.
@en
prefLabel
Triggers, targets and treatments for thrombosis.
@ast
Triggers, targets and treatments for thrombosis.
@en
P2860
P356
P1433
P1476
Triggers, targets and treatments for thrombosis.
@en
P2093
Nigel Mackman
P2860
P2888
P304
P356
10.1038/NATURE06797
P407
P577
2008-02-01T00:00:00Z
P5875
P6179
1000197416